Biomarkers for efficacy of adjuvant chemotherapy following complete resection in NSCLC stages I-IIIA.

ABSTRACT: Biomarkers may be useful when deciding which nonsmall cell lung cancer (NSCLC) patients may benefit from adjuvant chemotherapy following complete resection and which chemotherapeutic agents may be used preferably in individual patients in order to maximise survival. A literature search covering the period from 2003 to May, 2014 was conducted using PubMed and the following search terms: "non-small cell lung cancer", "NSCLC", "adjuvant chemotherapy", "randomized", "randomised", "biomarkers", "prognostic", "predictive". This review focuses on current knowledge of biomarkers for prognosis or efficacy of adjuvant treatment following complete resection in stage I-IIIA NSCLC patients. This review includes results on 18 different biomarkers and five gene profiles. A statistically significant progn

SUBMITTER: Wallerek S 

PROVIDER: S-EPMC9487808 | biostudies-literature | 2015 Jun

REPOSITORIES: biostudies-literature